annual cash & cash equivalents:
$72.31M+$49.35M(+215.01%)Summary
- As of today (June 4, 2025), LGND annual cash & cash equivalents is $72.31 million, with the most recent change of +$49.35 million (+215.01%) on December 31, 2024.
- During the last 3 years, LGND annual cash & cash equivalents has risen by +$52.78 million (+270.39%).
- LGND annual cash & cash equivalents is now -54.87% below its all-time high of $160.20 million, reached on December 31, 2014.
Performance
LGND Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$47.99M-$24.32M(-33.63%)Summary
- As of today (June 4, 2025), LGND quarterly cash & cash equivalents is $47.99 million, with the most recent change of -$24.32 million (-33.63%) on March 31, 2025.
- Over the past year, LGND quarterly cash & cash equivalents has dropped by -$2.10 million (-4.20%).
- LGND quarterly cash & cash equivalents is now -89.50% below its all-time high of $456.92 million, reached on September 30, 2020.
Performance
LGND quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
LGND Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +215.0% | -4.2% |
| 3 y3 years | +270.4% | +220.1% |
| 5 y5 years | +1.1% | -59.2% |
LGND Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +270.4% | -45.9% | +1065.9% |
| 5 y | 5-year | at high | +270.4% | -89.5% | +1065.9% |
| alltime | all time | -54.9% | +2061.0% | -89.5% | +6755.6% |
LGND Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $47.99M(-33.6%) |
| Dec 2024 | $72.31M(+215.0%) | $72.31M(+13.7%) |
| Sep 2024 | - | $63.62M(+250.7%) |
| Jun 2024 | - | $18.14M(-63.8%) |
| Mar 2024 | - | $50.09M(+118.2%) |
| Dec 2023 | $22.95M(-49.0%) | $22.95M(+19.1%) |
| Sep 2023 | - | $19.27M(-32.2%) |
| Jun 2023 | - | $28.45M(-67.9%) |
| Mar 2023 | - | $88.73M(+97.1%) |
| Dec 2022 | $45.01M(+130.5%) | $45.01M(+993.4%) |
| Sep 2022 | - | $4.12M(-22.0%) |
| Jun 2022 | - | $5.28M(-64.8%) |
| Mar 2022 | - | $14.99M(-23.2%) |
| Dec 2021 | $19.52M(-59.0%) | $19.52M(-16.7%) |
| Sep 2021 | - | $23.43M(+7.2%) |
| Jun 2021 | - | $21.86M(-31.4%) |
| Mar 2021 | - | $31.85M(-33.1%) |
| Dec 2020 | $47.62M(-33.4%) | $47.62M(-89.6%) |
| Sep 2020 | - | $456.92M(+296.8%) |
| Jun 2020 | - | $115.16M(-2.0%) |
| Mar 2020 | - | $117.53M(+64.3%) |
| Dec 2019 | $71.54M(-38.9%) | $71.54M(-68.2%) |
| Sep 2019 | - | $225.30M(-17.5%) |
| Jun 2019 | - | $273.05M(+159.8%) |
| Mar 2019 | - | $105.11M(-10.3%) |
| Dec 2018 | $117.16M(+468.2%) | $117.16M(+1.4%) |
| Sep 2018 | - | $115.56M(-23.7%) |
| Jun 2018 | - | $151.46M(+196.8%) |
| Mar 2018 | - | $51.02M(+147.4%) |
| Dec 2017 | $20.62M(+10.0%) | $20.62M(-37.0%) |
| Sep 2017 | - | $32.74M(-45.6%) |
| Jun 2017 | - | $60.22M(+466.0%) |
| Mar 2017 | - | $10.64M(-43.3%) |
| Dec 2016 | $18.75M(-80.8%) | $18.75M(-78.3%) |
| Sep 2016 | - | $86.58M(+41.1%) |
| Jun 2016 | - | $61.35M(+96.1%) |
| Mar 2016 | - | $31.29M(-67.9%) |
| Dec 2015 | $97.43M(-39.2%) | $97.43M(+3.9%) |
| Sep 2015 | - | $93.77M(-13.4%) |
| Jun 2015 | - | $108.24M(-34.7%) |
| Mar 2015 | - | $165.77M(+3.5%) |
| Dec 2014 | $160.20M(+1276.4%) | $160.20M(-11.3%) |
| Sep 2014 | - | $180.66M(+1142.8%) |
| Jun 2014 | - | $14.54M(+12.0%) |
| Mar 2014 | - | $12.98M(+11.5%) |
| Dec 2013 | $11.64M(-6.0%) | $11.64M(+255.8%) |
| Sep 2013 | - | $3.27M(-44.8%) |
| Jun 2013 | - | $5.92M(+17.6%) |
| Mar 2013 | - | $5.04M(-59.3%) |
| Dec 2012 | $12.38M(+75.8%) | $12.38M(+75.7%) |
| Sep 2012 | - | $7.05M(-20.7%) |
| Jun 2012 | - | $8.88M(-9.1%) |
| Mar 2012 | - | $9.78M(+38.9%) |
| Dec 2011 | $7.04M(+110.4%) | $7.04M(+212.8%) |
| Sep 2011 | - | $2.25M(-34.6%) |
| Jun 2011 | - | $3.44M(-43.0%) |
| Mar 2011 | - | $6.03M(+80.3%) |
| Dec 2010 | $3.35M(-79.1%) | $3.35M(-11.9%) |
| Sep 2010 | - | $3.80M(+17.3%) |
| Jun 2010 | - | $3.23M(-20.0%) |
| Mar 2010 | - | $4.04M(-74.8%) |
| Dec 2009 | $16.03M | $16.03M(+210.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2009 | - | $5.16M(+45.4%) |
| Jun 2009 | - | $3.55M(-27.9%) |
| Mar 2009 | - | $4.92M(-82.9%) |
| Dec 2008 | $28.75M(-62.6%) | $28.75M(+143.6%) |
| Sep 2008 | - | $11.80M(-59.6%) |
| Jun 2008 | - | $29.18M(-51.0%) |
| Mar 2008 | - | $59.54M(-22.5%) |
| Dec 2007 | $76.81M(-51.5%) | $76.81M(+10.8%) |
| Sep 2007 | - | $69.30M(-33.1%) |
| Jun 2007 | - | $103.61M(-74.3%) |
| Mar 2007 | - | $403.91M(+155.0%) |
| Dec 2006 | $158.40M(+137.3%) | $158.40M(+1479.4%) |
| Sep 2006 | - | $10.03M(-75.9%) |
| Jun 2006 | - | $41.62M(-16.4%) |
| Mar 2006 | - | $49.81M(-25.4%) |
| Dec 2005 | $66.76M(-27.7%) | $66.76M(+34.6%) |
| Sep 2005 | - | $49.59M(+52.2%) |
| Jun 2005 | - | $32.58M(-36.1%) |
| Mar 2005 | - | $50.96M(-44.8%) |
| Dec 2004 | $92.31M(+56.4%) | $92.31M(+100.6%) |
| Sep 2004 | - | $46.02M(+9.8%) |
| Jun 2004 | - | $41.92M(-36.1%) |
| Mar 2004 | - | $65.56M(+11.1%) |
| Dec 2003 | $59.03M(+39.1%) | $59.03M(-19.1%) |
| Sep 2003 | - | $73.00M(+201.1%) |
| Jun 2003 | - | $24.25M(+86.8%) |
| Mar 2003 | - | $12.98M(-69.4%) |
| Dec 2002 | $42.42M(+104.5%) | $42.42M(+83.0%) |
| Sep 2002 | - | $23.18M(-7.6%) |
| Jun 2002 | - | $25.09M(+37.9%) |
| Mar 2002 | - | $18.19M(-12.3%) |
| Dec 2001 | $20.74M(+124.9%) | $20.74M(+16.8%) |
| Sep 2001 | - | $17.75M(-37.9%) |
| Jun 2001 | - | $28.60M(+36.4%) |
| Mar 2001 | - | $20.97M(+127.4%) |
| Dec 2000 | $9.22M(-69.2%) | $9.22M(-22.9%) |
| Sep 2000 | - | $11.97M(-48.3%) |
| Jun 2000 | - | $23.16M(-3.0%) |
| Mar 2000 | - | $23.88M(-20.1%) |
| Dec 1999 | $29.90M(-8.8%) | $29.90M(+12.0%) |
| Sep 1999 | - | $26.70M(+217.9%) |
| Jun 1999 | - | $8.40M(-23.6%) |
| Mar 1999 | - | $11.00M(-66.5%) |
| Dec 1998 | $32.80M(-47.4%) | $32.80M(+31.7%) |
| Sep 1998 | - | $24.90M(-2.7%) |
| Jun 1998 | - | $25.60M(-1.9%) |
| Mar 1998 | - | $26.10M(-58.1%) |
| Dec 1997 | $62.30M(+79.0%) | $62.30M(+364.9%) |
| Sep 1997 | - | $13.40M(-24.3%) |
| Jun 1997 | - | $17.70M(-22.4%) |
| Mar 1997 | - | $22.80M(-34.5%) |
| Dec 1996 | $34.80M(+117.5%) | $34.80M(+397.1%) |
| Sep 1996 | - | $7.00M(-37.5%) |
| Jun 1996 | - | $11.20M(-32.1%) |
| Mar 1996 | - | $16.50M(+3.1%) |
| Dec 1995 | $16.00M(+110.5%) | $16.00M(+31.1%) |
| Sep 1995 | - | $12.20M(-8.3%) |
| Mar 1995 | - | $13.30M(+75.0%) |
| Dec 1994 | $7.60M | $7.60M(-37.2%) |
| Sep 1994 | - | $12.10M(+1628.6%) |
| Jun 1994 | - | $700.00K(-66.7%) |
| Mar 1994 | - | $2.10M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual cash & cash equivalents year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly cash & cash equivalents year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual cash & cash equivalents?
The current annual cash & cash equivalents of LGND is $72.31M
What is the all time high annual cash & cash equivalents for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual cash & cash equivalents is $160.20M
What is Ligand Pharmaceuticals Incorporated annual cash & cash equivalents year-on-year change?
Over the past year, LGND annual cash & cash equivalents has changed by +$49.35M (+215.01%)
What is Ligand Pharmaceuticals Incorporated quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of LGND is $47.99M
What is the all time high quarterly cash & cash equivalents for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly cash & cash equivalents is $456.92M
What is Ligand Pharmaceuticals Incorporated quarterly cash & cash equivalents year-on-year change?
Over the past year, LGND quarterly cash & cash equivalents has changed by -$2.10M (-4.20%)